Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Merck
Moodys
Baxter
Boehringer Ingelheim

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR LOPINAVIR AND RITONAVIR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


505(b)(2) Clinical Trials for Lopinavir And Ritonavir

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00196625 ↗ Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure. Completed French National Agency for Research on AIDS and Viral Hepatitis Phase 2 2000-11-01 HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Lopinavir And Ritonavir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004578 ↗ ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Na├»ve HIV-Infected Subjects Completed Abbott Phase 1/Phase 2 1997-11-01 To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.
NCT00006144 ↗ A Study of HIV-Disease Development in Aging Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2000-10-01 The purpose of this study is to better understand the relationship between age and HIV disease progression. This study will explore the possible relationship between age and HIV disease progression. Older age is an important risk factor for faster disease development, but older people may respond better to combination drug therapy. This relationship needs to be understood better.
NCT00014937 ↗ Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen. This study will compare the ability of two different three-drug anti-HIV drug regimens to reduce levels of HIV in the blood. The study will also evaluate whether patients discontinue the regimens because of drug side effects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lopinavir And Ritonavir

Condition Name

Condition Name for Lopinavir And Ritonavir
Intervention Trials
HIV Infections 139
COVID-19 36
HIV 35
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lopinavir And Ritonavir
Intervention Trials
HIV Infections 194
COVID-19 69
Acquired Immunodeficiency Syndrome 43
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lopinavir And Ritonavir

Trials by Country

Trials by Country for Lopinavir And Ritonavir
Location Trials
United States 755
Spain 88
Thailand 66
Canada 56
South Africa 54
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lopinavir And Ritonavir
Location Trials
California 61
New York 55
Florida 42
Texas 40
Illinois 40
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lopinavir And Ritonavir

Clinical Trial Phase

Clinical Trial Phase for Lopinavir And Ritonavir
Clinical Trial Phase Trials
Phase 4 90
Phase 3 76
Phase 2/Phase 3 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lopinavir And Ritonavir
Clinical Trial Phase Trials
Completed 219
Terminated 30
Recruiting 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lopinavir And Ritonavir

Sponsor Name

Sponsor Name for Lopinavir And Ritonavir
Sponsor Trials
Abbott 55
National Institute of Allergy and Infectious Diseases (NIAID) 51
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lopinavir And Ritonavir
Sponsor Trials
Other 503
Industry 147
NIH 86
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
AstraZeneca
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.